Discover
CLDX
Celldex Therapeutics, Inc.
44.27
1 x 44.25
6 x 44.34
bid
ask
+
1.30
3.02%
12:35 PM
timesize
| Ytd | 62.99% | |
| 1y | 121.23% |
42.65
day range
44.33
20.19
52 week range
44.33
| Open | 43.00 | Prev Close | 42.97 | Low | 42.65 | High | 44.33 | Mkt Cap | 2.95B |
| Vol | 302.23K | Avg Vol | 1.02M | EPS | -4.26 | P/E | -10.39 | Forward P/E | -9.96 |
| Beta | 0.87 | Short Ratio | 5.80 | Inst. Own | 100.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 35.26 | 200-d Avg | 30.06 | 1yr Est | 58.07 |
| Income Statement | |||
| Total Revenue | 22.00K | ||
| Revenues (USD) | 22.00K | ||
| Gross Profit | 22.00K | ||
| Operating Expenses | 80.65M | ||
| Research and Development Expense | 67.54M | ||
| Selling, General and Administrative Expense | 13.10M | ||
| Operating Income | -80.62M | ||
| Net Income | -73.50M | ||
| Net Income Common Stock | -73.50M | ||
| Net Income Common Stock (USD) | -73.50M | ||
| Consolidated Income | -73.50M | ||
| Earnings per Basic Share | -0.94 | ||
| Earnings per Basic Share (USD) | -0.94 | ||
| Earnings per Diluted Share | -0.94 | ||
| Earning Before Interest & Taxes (EBIT) | -73.50M | ||
| Earning Before Interest & Taxes (USD) | -73.50M | ||
| Weighted Average Shares | 77.84M | ||
| Weighted Average Shares Diluted | 77.84M | ||
| Balance Sheet | |||
| Cash and Equivalents | 47.45M | ||
| Cash and Equivalents (USD) | 47.45M | ||
| Investments | 670.13M | ||
| Investments Current | 670.13M | ||
| Trade and Non-Trade Receivables | 230.00K | ||
| Current Assets | 724.93M | ||
| Property, Plant & Equipment Net | 14.79M | ||
| Total Assets | 782.35M | ||
| Debt Current | 1.56M | ||
| Total Debt | 4.90M | ||
| Current Liabilities | 61.33M | ||
| Debt Non-Current | 3.35M | ||
| Total Liabilities | 67.79M | ||
| Accumulated Retained Earnings (Deficit) | -1.97B | ||
| Accumulated Other Comprehensive Income | 1.30M | ||
| Shareholders Equity | 714.56M | ||
| Shareholders Equity (USD) | 714.56M | ||
| Assets Non-Current | 57.42M | ||
| Total Debt (USD) | 4.90M | ||
| Goodwill and Intangible Assets | 27.19M | ||
| Liabilities Non-Current | 6.46M | ||
| Trade and Non-Trade Payables | 14.68M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 902.00K | ||
| Net Cash Flow from Financing | 324.66M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 11.73M | ||
| Capital Expenditure | -3.18M | ||
| Issuance (Purchase) of Equity Shares | 324.66M | ||
| Net Cash Flow from Investing | -255.52M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -252.34M | ||
| Net Cash Flow from Operations | -57.41M | ||
| Share Based Compensation | 8.41M | ||